Sanofi to buy Vigil Neuroscience in USD 470 million deal Ruchika Sharma22 May 2025 12:33 PM ISTParis: Sanofi has announced that it has entered into an agreement to acquire Vigil Neuroscience, Inc., a publicly traded clinical-stage...
Sanofi sells controlling stake of consumer healthcare business Opella Ruchika Sharma2 May 2025 3:35 PM ISTParis: Sanofi has announced the closing of the sale to CD&R of a 50.0% controlling stake of its consumer healthcare business Opella. Sanofi...
Sanofi invests Euro 15 milion in Innate Pharma Ruchika Sharma25 April 2025 2:30 PM ISTMarseille: Innate Pharma SA has announced a €14,999,998.59 capital increase subscribed by Sanofi.As announced on April 23, 2025, and given the...
FDA Approves Dupilumab as First New Targeted Therapy for Chronic Spontaneous Urticaria in Over a Decade Dr. Kamal Kant Kohli21 April 2025 9:15 PM ISTThe US Food and Drug Administration (FDA) has approved dupilumab (Dupixent) for the treatment of chronic spontaneous urticaria (CSU) in patients aged...
CDSCO Panel Approves Sanofi's Protocol Amendment to study Tolebrutinib Dr. Divya Colin20 April 2025 5:15 PM ISTNew Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organization (CDSCO) has approved Sanofi's proposal...
Sanofi, Regeneron Pharma secures USFDA approval for Dupixent for chronic spontaneous urticaria Ruchika Sharma19 April 2025 1:15 PM ISTParis: Sanofi and Regeneron Pharma have received approval from the US Food and Drug Administration (FDA) for Dupixent (dupilumab) for the...
USFDA grants orphan drug designation to Sanofi Rilzabrutinib for two rare diseases Ruchika Sharma3 April 2025 2:45 PM ISTParis: Sanofi has announced that the US Food and Drug Administration (FDA) has granted orphan drug designation to Rilzabrutinib, an...
FDA Approves fitusiran for Hemophilia A and B Dr. Kamal Kant Kohli2 April 2025 9:15 AM ISTThe FDA has approved fitusiran, now named Qfitlia, for routine prophylaxis in patients aged 12 and older with hemophilia A or B, with or without...
Sanofi Dupixent approved in Japan for COPD Ruchika Sharma30 March 2025 10:00 AM ISTDupixent is intended for injection under the skin (subcutaneous injection) and is given every other week.
USFDA approves Sanofi Qfitlia for hemophilia A or B with or without inhibitors Ruchika Sharma29 March 2025 11:30 AM ISTParis: Sanofi has announced that the Company has received approval from the US Food and Drug Administration (FDA) for Qfitlia...
Sanofi gets USFDA fast track designation for Chlamydia vaccine candidate Ruchika Sharma27 March 2025 3:22 PM ISTParis: Sanofi has received the US Food and Drug Administration (USFDA) fast-track designation for its mRNA vaccine candidate for the...
Sanofi Tolebrutinib under USFDA priority review for multiple sclerosis Ruchika Sharma25 March 2025 12:15 PM ISTTolebrutinib is currently under clinical investigation, and its safety and efficacy have not been evaluated by any regulatory authority.
